

Agent Number 3387 Cetirizine

Last Updated 11/24/2022

Agent Summary

Quick take: Based on experimental animal studies and reported human experience, cetirizine and levocetirizine are not believed to increase the risk of adverse pregnancy outcome.

Cetirizine, an antihistamine, is a metabolite of hydroxyzine [#1101](#). Brand names include Zyrtec (8), Reactine, Alleroff, and Certex-24. The active enantiomer, levocetirizine, is marketed as Xyzal (9).

Experimental animal development

Administration at up to 40, 180, and 216 times the human dose in pregnant mice, rats, and rabbits, respectively, did not produce an increase in congenital malformations in the offspring. Levocetirizine did not increase abnormal pregnancy outcome in rats or rabbits at 300-400 times the human dose (9). The prevalence of malformations was not increased among the offspring of pregnant rats or rabbits treated with up to 500 times the maximum human dose of cetirizine (1).

Human pregnancy reports

In human births with first trimester exposure to cetirizine there were no increases in spontaneous or therapeutic abortion, stillbirth, birth defects, abnormal birth weight, or abnormal gestational age at delivery (2-5,11). Among 917 pregnancies with exposure to cetirizine the prevalence of malformations was similar to that in the general population (6). No association was found between cetirizine use during pregnancy and facial clefts or hypospadias (7). Among 228 pregnancies with cetirizine exposure there was no increase in adverse pregnancy outcomes including malformations (12). Most of the exposures occurred

during the first trimester. Cetirizine was associated in a case-control study with truncus arteriosus and tetralogy of Fallot, although the associations may have been influenced by multiple comparisons (13).

Lactation

Preclinical studies reported in the product labeling found decreased weight gain in pups nursed by mice given 40 times the human dose level of cetirizine (9). About 3% of the maternal dose was detectable in the milk of dogs. The labeling stated that human milk contained cetirizine, but information on milk concentrations was not supplied. Although the labeling stated that use in nursing mothers is not recommended, we have not located data to permit an estimate of human risk, if any, from such exposure. A case report described a mother who was taking sodium oxybate [#3838](#) and cetirizine, among other agents, and successfully nursed for 6 months with normal growth in the infant (10). Milk concentrations were estimated to expose infants to 1.77% of the weight-adjusted maternal dose (14). Three nursing mothers taking cetirizine did not report adverse effects in their infants. Among 228 human milk samples, the cetirizine concentration was 0.65-65 ng/mL (15).

Reproduction

According to the product labeling, cetirizine did not impair fertility in mice at up to 64 mg/kg/day, about 26 times the human dose on a surface area basis (8).

Selected References

1. Kamijima M, Sakai Y, Kinoshita K, Aruga K, Morimoto K, Kawakami T: Reproductive and developmental toxicity studies of cetirizine in rats and rabbits. The Clinical Report 28:1877-1903, 1994.
2. Einarson A, Bailey B, Jung G, Spizzirri JD, Baillie M, Koren G: Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997 78:183-6.
3. Wilton LV, Pearce GL, Martin RM, et al.: The outcomes of pregnancy in women exposed to newly marketed drugs in

- general practice in England. Br J Obstet Gynaecol 105:882-889, 1998.
4. Paulus W, Schloemp S, Sterzik K, Stoz F. Pregnancy outcome after exposure to cetirizine/levocetirizine in the first trimester- a prospective controlled study. Reprod Toxicol 2004;19:258.
 5. Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational study. Reprod Toxicol 2008;26:19-23.
 6. Kallen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002;11:146-152.
 7. Anderka M, Mitchell AA, Louik C, Werler MM, Hernandez-Diaz S, Rasmussen SA, and the National Birth Defects Prevention Study. Birth Defects Res (Part A) 2012;94:22-30.
 8. Zyrtec. Product Labeling.
03/17/2004 <http://www.accessdata.fda.gov/drugsatfda/docs/label/2004/19835slr016,21150slr005,30346slr011zyrteclbl.pdf>
 9. Xyzal. Product Labeling.
11/07/2013. <http://www.accessdata.fda.gov/drugsatfda/docs/label/2013/022064s028022157s012lbl.pdf>
 10. Gashlin LZ, Sullo D, Lawrence RA, Rosen-Carole C. Treatment Of Narcolepsy With Sodium Oxybate While Breastfeeding: A case report. Breastfeed Med 2016; PMID 27057786.
 11. Etwel F, Djokanovic N, Moretti ME, Boskovic R, Martinovic J, Koren G. The fetal safety of cetirizine: an observational cohort study and meta-analysis. J Obstet Gynaecol. 2014 Jul;34(5):392-9. doi: 10.3109/01443615.2014.896887. PubMed PMID: 24678814.
 12. Golembesky A, Cooney M, Boev R, Schlit AF, Bentz JW. 2018. Safety of cetirizine in pregnancy. J Obstet Gynaecol 38(7): 940-945.
 13. Hansen C, Desrosiers T, Wisniewski K, Strickland MJ, Werler MM, Gilboa SM. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011. Birth Defects Res 2020;112:1234-1252.
 14. Wilkerson H, Datta P, Rewers-Felkins K, Baker T, Hale TW. Maternal transfer of cetirizine into human milk. J Hum Lact.

2021 Feb;37(1):135-138. doi: 10.1177/0890334420949847. Epub
2020 Aug 27. PMID: 32853084.

15. Wegler C, Saleh A, Lindqvist A, Nordeng H, Smeraglia J, Baranczewski P. 2022. Simple and rapid quantification of cetirizine, venlafaxine, and O-desmethylvenlafaxine in human breast milk, and metformin in human milk and plasma with UHPLC-MS/MS. *J Chromatogr B Analyt Technol Biomed Life Sci* 1205: 123340.
[https://linkinghub.elsevier.com/retrieve/pii/S1570-0232\(22\)00244-6](https://linkinghub.elsevier.com/retrieve/pii/S1570-0232(22)00244-6)

/rtc